Novavax, Inc. (FRA:NVV1)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.45B +26.4% |
| Revenue (ttm) | 362.20M -61.6% |
| Net Income | -216.84M |
| EPS | -1.33 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40 |
| Open | 8.63 |
| Previous Close | 9.00 |
| Day's Range | 8.63 - 8.72 |
| 52-Week Range | 5.41 - 10.03 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Novavax
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in ... [Read more]
News
Novavax Transcript: Citigroup’s Biopharma Back to School Summit 2026
The discussion highlighted a strategic shift to out-licensing and partnerships, with Sanofi and Pfizer driving near-term milestones and global expansion. Matrix-M's potential in oncology and infectious diseases is being explored, while NUVAXOVID's U.S. launch and combination vaccine prospects are set to drive growth.
Novavax Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A major strategic pivot has shifted focus to licensing and partnerships, with Matrix-M technology now central to both infectious disease and oncology pipelines. Key alliances with top pharma, strong financial milestones, and a leaner structure position the company for sustainable growth and global impact.
Novavax to Participate in September Investor Conferences
GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Globa...
Novavax’s partners approved for Nuvaxovid formulation for vaccination season
Novavax’s (NVAX) partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European ...
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
COVID-19 remains a public health challenge, particularly among older adults and high-risk populations 1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable toler...
US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
Novavax Earnings Call Transcript: Q2 2026
Q2 2026 saw strong progress in partnerships, notably with Sanofi and Pfizer, and a 76% year-over-year increase in product sales, despite lower total revenue due to prior year milestones. Operating expenses dropped 36%, and guidance was raised for 2026 revenue and profitability targets.
Novavax Quarterly report: Q2 2026
Novavax has published its Q2 2026 quarterly earnings report on August 6, 2026.
Novavax Earnings release: Q2 2026
Novavax released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Novavax Slides: Q2 2026
Novavax has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Novavax reports Q2 EPS (32c), consensus (38c)
Reports Q2 revenue $56.7M, consensus $53.3M. “We’re encouraged by the momentum we’re seeing across our business as we continue to advance our strategy,” said CEO John Jacobs. “As we enter…
Novavax raises 2026 adjusted revenue view to $235M-$275M from $230M-$270M
2026 revenue consensus $388.95M.
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
Novavax raised its annual revenue forecast after beating quarterly expectations on Thursday, as the vaccine maker's licensing-driven milestone payments helped offset waning demand.
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanof...
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. fi...
Novavax put volume heavy and directionally bearish
Bearish flow noted in Novavax (NVAX) with 2,130 puts trading, or 4x expected. Most active are Jul-26 8 puts and 7/31 weekly 8 puts, with total volume in those strikes…
Shah Capital Responds to Significant Shareholder Dissent at Novavax AGM
RALEIGH, N.C., June 24, 2026 (GLOBE NEWSWIRE) -- Shah Capital, the largest shareholder of Novavax, today commented on yesterday's announced voting results from Novavax's June 18th 2026 Annual Meeting ...
Novavax put volume heavy and directionally bearish
Bearish flow noted in Novavax (NVAX) with 8,291 puts trading, or 12x expected. Most active are Jul-26 8 puts and 6/26 weekly 9.5 calls, with total volume in those strikes…
Novavax Transcript: AGM 2026
The meeting covered director elections, executive compensation, amendments to stock plans, and auditor ratification, with all proposals approved by majority vote. Quorum was confirmed, and final results will be filed with the SEC.
Novavax Transcript: Jefferies Global Healthcare Conference 2026
A new growth strategy launched in 2025 emphasizes immediate monetization through major partnerships, notably with Pfizer and Sanofi, and a non-exclusive licensing model to maximize revenue streams. Matrix-M technology is being advanced in infectious disease and oncology, with a robust internal pipeline and significant cost reductions targeting non-GAAP profitability by 2028.
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
GAITHERSBURG, Md., June 1, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference.
Novavax Transcript: Bank of America Global Healthcare Conference 2026
A major strategic pivot has transformed the business into a technology platform focused on Matrix-M partnerships, generating significant interest and deals with leading pharma companies. The company expects substantial milestone and royalty revenues, a leaner cost structure, and non-GAAP profitability as early as 2028, with a robust pipeline and ongoing R&D supporting future growth.
Novavax Slides: Corporate presentation
Novavax has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Novavax to Participate in BofA Securities 2026 Health Care Conference
GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.